The estimated Net Worth of Michael Sinclair is at least $5.13 millió dollars as of 13 June 2022. Michael Sinclair owns over 13,616 units of Opiant Pharmaceuticals Inc stock worth over $396,893 and over the last 5 years he sold OPNT stock worth over $1,381,507. In addition, he makes $3,354,630 as Executive Chairman of the Board at Opiant Pharmaceuticals Inc.
Sign up
Michael Sinclair OPNT stock SEC Form 4 insiders trading
Michael has made over 6 trades of the Opiant Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 13,616 units of OPNT stock worth $149,231 on 13 June 2022.
The largest trade he's ever made was exercising 150,000 units of Opiant Pharmaceuticals Inc stock on 23 August 2021 worth over $750,000. On average, Michael trades about 32,500 units every 126 days since 2019. As of 13 June 2022 he still owns at least 19,220 units of Opiant Pharmaceuticals Inc stock.
You can see the complete history of Michael Sinclair stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Sinclair biography
Dr. Michael J. Sinclair is Executive Chairman of the Board of Lightlake Therapeutics Inc. Dr. Sinclair qualified as a physician in 1967, specializing in psychiatry. He has built both private and public healthcare businesses, establishing medical facilities and hospitals in the US, Middle East, East Asia, Australia and UK, including the Portland in London, which was his personal vision to launch the first private hospital in Britain dedicated to treating women and children. He serves on the Board of Overseers (Emeritus) of Tufts University Medical School, where, together with Dean Mort Madoff, he founded the US’ first combined MD/MBA program. Dr. Sinclair has been the Chairman of Symthera Inc., Advanced Oncotherapy Plc., and Emess Biosciences Ltd.
What is the salary of Michael Sinclair?
As the Executive Chairman of the Board of Opiant Pharmaceuticals Inc, the total compensation of Michael Sinclair at Opiant Pharmaceuticals Inc is $3,354,630. There are 1 executives at Opiant Pharmaceuticals Inc getting paid more, with Roger Crystal having the highest compensation of $5,413,730.
How old is Michael Sinclair?
Michael Sinclair is 77, he's been the Executive Chairman of the Board of Opiant Pharmaceuticals Inc since 2012. There are no older and 9 younger executives at Opiant Pharmaceuticals Inc.
What's Michael Sinclair's mailing address?
Michael's mailing address filed with the SEC is C/O OPIANT PHARMACEUTICALS, INC., 233 WILSHIRE BLVD, SUITE 400, SANTA MONICA, CA, 90401.
Insiders trading at Opiant Pharmaceuticals Inc
Over the last 21 years, insiders at Opiant Pharmaceuticals Inc have traded over $16,027,532 worth of Opiant Pharmaceuticals Inc stock and bought 199,545 units worth $2,080,156 . The most active insiders traders include Craig A Collard, Marc A Cohen és Alain J Cohen. On average, Opiant Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $159,046. The most recent stock trade was executed by Roger Crystal on 27 January 2023, trading 1,358 units of OPNT stock currently worth $27,513.
What does Opiant Pharmaceuticals Inc do?
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
What does Opiant Pharmaceuticals Inc's logo look like?
Complete history of Michael Sinclair stock trades at Opiant Pharmaceuticals Inc
Opiant Pharmaceuticals Inc executives and stock owners
Opiant Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Roger Crystal,
President, Chief Executive Officer, Director -
Michael Sinclair,
Executive Chairman of the Board -
Dr. Roger Crystal,
Pres, CEO & Director -
Dr. Phil Skolnick D.Sc. (hon), Ph.D.,
Chief Scientific Officer -
David D. O'Toole,
Chief Financial Officer -
Michael Porter,
IR Contact Officer -
Richard Daly,
Independent Director -
Craig Collard,
Independent Director -
Thomas Thomas,
Director -
Gabrielle Silver,
Director -
Ann MacDougall,
Director -
Aziz Mottiwala,
Chief Commercial Officer -
Rahsaan Thompson,
General Counsel -
Phil Skolnick,
Chief Scientific Officer -
Arvind Agrawal,
Executive Vice President - Medical Affairs -
David O'Toole,
Chief Financial Officer -
Matthew R. Ruth,
Chief Commercial Officer -
Dr. Mark Heath Ellison Ph.D.,
Chief Devel. Officer -
Brian Gorman,
EVP Corp. Devel. & Gen. Counsel -
Ben Atkins,
VP of Communications & Investor Relations -
Matthew R. Ruth,
Chief Commercial Officer -
Ronald W Kaiser,
Director -
Melvin Iii Wesley,
Chief Financial Officer -
William F Stasior,
Director -
Steven G Finn,
Director -
Joseph W Kuhn,
VP & Chief Financial Officer -
Alain J Cohen,
President & Chief Tech Officer -
Marc A Cohen,
Chairman, CEO, Treas, & Sec -
Brian Gorman,
-
Mark Jason Heath Ellison,
Chief Development Officer -
Masuoka K. Lorianne,
Director